Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy

Published:2024-01 Issue:1 Volume:25 Page:e26-e34.e6
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Hashimoto Kohei,Murakami Yu,Omura Kenshiro,Takahashi Hikaru,Suzuki Ryoko,Yoshioka Yasuo,Oguchi Masahiko,Ichinose Junji,Matsuura Yosuke,Nakao Masayuki,Okumura Sakae,Ninomiya Hironori,Nishio Makoto,Mun Mingyon

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

2. Perioperative pembrolizumab for early-stage non-small-cell lung cancer;Wakelee;N Engl J Med,2023

3. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial;Chaft;Nat Med,2022

4. Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non–small cell lung cancer: results from a randomized trial;Lee;J Thorac Cardiovasc Surg,2023

5. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial;Provencio;Lancet Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP